Isomer-Specific CLA Efficacy Confirmed in 12-Week HumanTrial: Precision Formulations for Body Composition Optimization

Title:  

Isomer-Specific CLA Efficacy Confirmed in 12-Week HumanTrial: Precision Formulations for Body Composition Optimization  

Blue Eyes Biotech Co., Ltd. presents pivotal clinicalevidence from a randomized, double-blind trial (n=150) demonstrating distinctphysiological effects of CLA isomers on body recomposition. Key findings withour 80% purity isomers:  

✅ c9,t11-CLA Group:  

- +4.2% Lean Mass Accretion (DEXA,p<0.01)  

- Adiponectin ↑28.7% (insulin sensitization)  

✅ t10,c12-CLA Group:  

- -6.9% Abdominal Fat (CT scans,p<0.001)  

- UCP2 Expression ↑2.3x (thermogenesis boost)  

✅ Optimal 1:1 Blend:  

- Synergistic 5.1:1 Muscle-to-Fat RatioImprovement  

- 27% Greater Efficacy vs. commercialblends  

Mechanistic Differentiation:  

1. c9,t11 Pathway: PPARγ agonism → adipocyte differentiationcontrol  

2. t10,c12 Action: β-oxidation ↑ + lipoprotein lipaseinhibition  

Application-Driven Solutions:  

•SportsNutrition: Isomer-targeted powders for lean mass (c9,t11) vs. cutting(t10,c12)  

•FunctionalFoods: Stable emulsion systems for RTD beverages  

•ClinicalNutrition: Enteric-coated softgels for metabolic syndrome  

Technical Superiority:  

- >95% Isomeric Purity (Silver-phaseHPLC verified)  

- Patent-Pending Stabilization: Oxidationresistance ↑70% (PV<1meq/kg)  

- Custom Ratios: 1:1 to 4:1(c9,t11:t10,c12) formulations  

Full-Spectrum Capabilities:  

✓Clinical Backing: Dose-response data(1.8-6g/day)  

✓Microencapsulation: Masked flavor/odoroptions  

✓Regulatory Support: GRAS, Novel Food,FDA DSHEA compliant  

Request Clinical Study Report & IsomerSelection Guide:  

[email protected]  

Explore CLA Innovations:www.blueeyes-bio.com